Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13 - PubMed (original) (raw)
. 2010 Dec 16;116(25):5738-47.
doi: 10.1182/blood-2010-06-287839. Epub 2010 Aug 31.
Paulo C Rodriguez, Qing Zhou, Christine A Goetz, Brent H Koehn, Rachelle Veenstra, Patricia A Taylor, Angela Panoskaltsis-Mortari, Jonathan S Serody, David H Munn, Jakub Tolar, Augusto C Ochoa, Bruce R Blazar
Affiliations
- PMID: 20807889
- PMCID: PMC3031417
- DOI: 10.1182/blood-2010-06-287839
Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13
Steven L Highfill et al. Blood. 2010.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a well-defined population of cells that accumulate in the tissue of tumor-bearing animals and are known to inhibit immune responses. Within 4 days, bone marrow cells cultured in granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor resulted in the generation of CD11b(+)Ly6G(lo)Ly6C(+) MDSCs, the majority of which are interleukin-4Rα (IL-4Rα(+)) and F4/80(+). Such MDSCs potently inhibited in vitro allogeneic T-cell responses. Suppression was dependent on L-arginine depletion by arginase-1 activity. Exogenous IL-13 produced an MDSC subset (MDSC-IL-13) that was more potently suppressive and resulted in arginase-1 up-regulation. Suppression was reversed with an arginase inhibitor or on the addition of excess L-arginine to the culture. Although both MDSCs and MDSC-IL-13 inhibited graft-versus-host disease (GVHD) lethality, MDSC-IL-13 were more effective. MDSC-IL-13 migrated to sites of allopriming. GVHD inhibition was associated with limited donor T-cell proliferation, activation, and proinflammatory cytokine production. GVHD inhibition was reduced when arginase-1-deficient MDSC-IL-13 were used. MDSC-IL-13 did not reduce the graft-versus-leukemia effect of donor T cells. In vivo administration of a pegylated form of human arginase-1 (PEG-arg1) resulted in L-arginine depletion and significant GVHD reduction. MDSC-IL-13 and pegylated form of human arginase-1 represent novel strategies to prevent GVHD that can be clinically translated.
Figures
Figure 1
Generation and phenotype of cultured MDSCs. (A) Fluorescence-activated cell sorter phenotype of B6 whole BM at day 4 of culture that has been left untreated, treated with G-CSF alone (100 ng/mL), treated with GM-CSF alone (250 U/mL), or treated with both G-CSF and GM-CSF. All gates based on isotype controls. Ly6G/Ly6C graphs were first gated on CD11b+ cells. Representative images of hematoxylin and eosin-stained cytospins of MDSCs with combined treatment (B) and combined treatment plus IL-13 addition on day 3 (C) Photographs were taken using 400× magnification with a RT-Spot camera mounted on an Olympus BX51 microscope (Olympus).
Figure 2
MDSCs inhibit T-cell alloresponses through the expression of arginase-1. (A) RT-PCR showing that MDSCs express arginase-1 and iNOS and up-regulate arginase-1 on stimulation with IL-13. Hypoxanthine phosphoribosyl transferase shown as endogenous control. M indicates marker. (B) Real-time RT-PCR showing quantitatively the extent of arginase-1 and iNOS up-regulation by IL-13-stimulated MDSCs. Standardized to glyceraldehyde-3-phosphate dehydrogenase endogenous control and relative expression compared with untreated BM. (C) Western blot showing arginase-1 and actin control at the protein level in untreated BM, MDSCs, and MDSC IL-13. (D) Arginase activity was determined by measuring the production of urea over time. MLR was performed by mixing B6 purified T cells with irradiated BALB/c stimulators (1:1 ratio) and MDSCs (1:10 ratio). Cultures were pulsed with 3H-thymidine on the indicated days and harvested after a 16-hour incubation. (E) MLR/MDSC cocultures were left untreated or were treated with arginase inhibitor, nor-NOHA (300μM), nitric oxide inhibitor, L-NMMA (300μM), or both. (F) Arginase inhibitor (nor-NOHA) was added to MLR/MDSC cocultures at increasing concentrations (30, 100, and 300μM). (G) B6 WT T cells or GCN2 KO T cells were used as responder cells, and MDSCs were added at 1:10 ratio. (H) Addition of excess L-arginine (5mM) or tryptophan (5mM) was added back to MLR/MDSC cocultures and assessed for T-cell proliferation.
Figure 3
MDSC-IL-13 migrate to sites of allopriming in a GVHD setting. (A) Fluorescence-activated cell sorter analysis of pretransplantation MDSC-IL-13 was gated on Gr1+CD11b+ and analyzed for the surface expression of molecules associated with homing and recruitment. Gates are based on isotype controls. (B) Lethally irradiated BALB/c recipients were given 107 BM cells plus 2 × 106 T cells with 6 × 106 eGFP transgenic MDSC-IL-13. Control mice were given BM and T cells only. On days 7 and 14, LN and spleen were harvested and imaged using macroscopic fluorescent imaging. (C) The absolute number of eGFP+ cells that had migrated to the LNs and spleen was determined using flow cytometry. (D) Spleen was harvested from day 7 transplanted mice, and flow cytometry was performed to determine whether MDSC-IL-13 retained Gr1+CD11b+ phenotype. Cells were gated on donor (GFP+) CD11b+ cells.
Figure 4
Cultured MDSC-IL-13 enhance GVHD survival in an arginase-1-dependent fashion. Lethally irradiated BALB/c recipients were given 107 B6 BM cells plus 2 × 106 purified CD25-depleted T cells plus either 2 × 106 MDSC-IL-13 or 6 × 106 MDSC-IL-13, both IL-13-treated. Kaplan-Meier survival curve of transplanted mice (A). Data represent 2 pooled experiments (BM only, N = 18; BM + T, N = 18; BM + T + 2 × 106 MDSC IL-13-tx, N = 22; BM + T + 6 × 106 MDSC- IL-13, N = 22; BM + T vs 2 × 106 MDSC IL-13, P < .001; BM + T vs 6 × 106 MDSC IL-13, P < .001; 2 × 106 MDSC IL-13 vs 6 × 106 MDSC- IL-13, P = .06). (B) Corresponding weights. (C) Kaplan-Meier survival curve of BM transplantation using 6 × 106 MDSC IL-13 generated from either WT mice or arginase-1 KO mice. Data represent one experiment (BM only, N = 8; BM + T, N = 12; BM + T + 6 × 106 WT MDSC-IL-13, N = 12; BM + T + 6 × 106 arginase-I KO MDSC-IL-13, N = 12; BM + T vs 6 × 106 WT MDSCs, P = .05; BM + T vs 6 × 106 arginase-I KO MDSC-IL-13, P = .08; arginase-1 KO MDSC-IL-13 vs WT MDSC-IL-13, P = .1). (D) Corresponding weights.
Figure 5
MDSC-IL-13 negatively impact proliferation, activation, and effector function of donor T cells. Lethally irradiated BALB/c mice were transplanted with 15 × 106 CFSE-labeled CD25-depleted B6 Ly5.1-expressing T cells alone or with 10 × 106 CD11b purified MDSC-IL-13. (A) Day 4 splenocytes were analyzed via flow cytometry for CFSE dilution on CD4 and CD8 T cells. (B) Flow cytometry was used to detect the amount of CD3ζ present on CD4 and CD8 splenic T cells. (C) Graph of common activation markers (CD25 and CD62L) on CD4 and CD8 splenic T cells. (D) Intracellular cytokine staining was performed on LN CD4 and CD8 T cells to determine the percentage of cells producing IFN-γ.
Figure 6
MDSCs preserve GVL effect of allogeneic donor T cells. Lethally irradiated BALB/c mice were given 10 × 106 B6 T cell–depleted BM cells alone or with 2 × 106 CD25-depleted B6 T cells. Cohorts of mice also received 3 × 105 A20 cells and/or 6 × 106 B6 MDSC-IL-13. All cells were given intravenously on day 0 of transplantation. (A) Kaplan-Meier survival curve of mice receiving BM only (N = 10), BM + T (N = 10), or BM + T + MDSC-IL-13 (N = 10). (B) Corresponding weights from these mice. (C) Kaplan-Meier survival curve of mice receiving BM + A20 (N = 10), BM + T + A20 (N = 10), or BM + T + A20 + MDSC-IL-13 (N = 10). (D) Corresponding weights. (E) Mice were monitored on days 14, 18, and 50 using bioluminescent imaging to detect Renilla luciferase-expressing A20 cells. BM + T versus BM + T + MDSCs, P < .001; BM + A20 versus BM + T + A20, P < .001; BM + T + A20 versus BM + T + A20 + MDSCs, P < .001. Data represent one experiment.
Figure 7
PEG-arg1 has similar protective effects as MDSC IL-13-tx. Lethally irradiated BALB/c mice were given 10 × 106 B6 BM cells alone or with 2 × 106 CD25-depleted T cells. In addition to this, cohorts were also given 6 × 106 MDSC IL-13 on day 0 or PEG-arg1 at 1 mg/mouse, 2 times weekly. (A) Kaplan-Meier survival curve. (B) Corresponding weights. P values for survival are BM + T versus 6 × 106 MDSCs, P = .03; BM + T versus PEG-arg1, P = .003. (C) L-Arginine was quantified using high performance liquid chromatography on day 14 from the peripheral blood of transplanted mice. WT B6 mice were used as controls. Data are representative of 2 replicate experiments with similar results.
Comment in
- Exploiting arginase to prevent GVHD.
Hallett W, Johnson B. Hallett W, et al. Blood. 2010 Dec 16;116(25):5440-1. doi: 10.1182/blood-2010-09-306431. Blood. 2010. PMID: 21163935 No abstract available.
Similar articles
- Graft-Versus-Host Disease Prevention by _In Vitro_-Generated Myeloid-Derived Suppressor Cells Is Exclusively Mediated by the CD11b+CD11c+ MDSC Subpopulation.
Scheurer J, Kitt K, Huber HJ, Fundel-Clemens K, Pflanz S, Debatin KM, Strauss G. Scheurer J, et al. Front Immunol. 2021 Oct 14;12:754316. doi: 10.3389/fimmu.2021.754316. eCollection 2021. Front Immunol. 2021. PMID: 34721430 Free PMC article. - In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity.
Messmann JJ, Reisser T, Leithäuser F, Lutz MB, Debatin KM, Strauss G. Messmann JJ, et al. Blood. 2015 Aug 27;126(9):1138-48. doi: 10.1182/blood-2015-01-624163. Epub 2015 Jul 16. Blood. 2015. PMID: 26185131 - GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.
Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H. Kohanbash G, et al. Cancer Res. 2013 Nov 1;73(21):6413-23. doi: 10.1158/0008-5472.CAN-12-4124. Epub 2013 Sep 12. Cancer Res. 2013. PMID: 24030977 Free PMC article. - Myeloid-Derived Suppressor Cells in Trypanosoma cruzi Infection.
Fresno M, Gironès N. Fresno M, et al. Front Cell Infect Microbiol. 2021 Aug 27;11:737364. doi: 10.3389/fcimb.2021.737364. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34513737 Free PMC article. Review. - Phenotype, development, and biological function of myeloid-derived suppressor cells.
Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Zhao Y, et al. Oncoimmunology. 2015 Oct 14;5(2):e1004983. doi: 10.1080/2162402X.2015.1004983. eCollection 2016 Feb. Oncoimmunology. 2015. PMID: 27057424 Free PMC article. Review.
Cited by
- The Interactions of T Cells with Myeloid-Derived Suppressor Cells in Peripheral Blood Stem Cell Grafts.
Guan Q, Gilpin SG, Doerksen J, Bath L, Lam T, Li Y, Lambert P, Wall DA. Guan Q, et al. Cells. 2024 Sep 14;13(18):1545. doi: 10.3390/cells13181545. Cells. 2024. PMID: 39329729 Free PMC article. - Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease.
Yang PJ, Zhao XY, Kou YH, Liu J, Ren XY, Zhang YY, Wang ZD, Ge Z, Yuan WX, Qiu C, Tan B, Liu Q, Shi YN, Jiang YQ, Qiu C, Guo LH, Li JY, Huang XJ, Yu LY. Yang PJ, et al. Acta Pharmacol Sin. 2024 May 27. doi: 10.1038/s41401-024-01283-y. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 38802569 - Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation.
Notarantonio AB, Bertrand A, Piucco R, Fievet G, Sartelet H, Boulangé L, de Isla N, De Carvalho Bittencourt M, Hergalant S, Rubio MT, D'Aveni M. Notarantonio AB, et al. Exp Hematol Oncol. 2024 May 11;13(1):50. doi: 10.1186/s40164-024-00516-4. Exp Hematol Oncol. 2024. PMID: 38734654 Free PMC article. - Extracellular release of damaged mitochondria induced by prehematopoietic stem cell transplant conditioning exacerbates GVHD.
Vijayan V, Yan H, Lohmeyer JK, Prentiss KA, Patil RV, Barbarito G, Lopez I, Elezaby A, Peterson K, Baker J, Ostberg NP, Bertaina A, Negrin RS, Mochly-Rosen D, Weinberg K, Haileselassie B. Vijayan V, et al. Blood Adv. 2024 Jul 23;8(14):3691-3704. doi: 10.1182/bloodadvances.2023012328. Blood Adv. 2024. PMID: 38701354 Free PMC article. - Intracerebellar injection of monocytic immature myeloid cells prevents the adverse effects caused by stereotactic surgery in a model of cerebellar neurodegeneration.
Del Pilar C, Garrido-Matilla L, Del Pozo-Filíu L, Lebrón-Galán R, Arias RF, Clemente D, Alonso JR, Weruaga E, Díaz D. Del Pilar C, et al. J Neuroinflammation. 2024 Feb 14;21(1):49. doi: 10.1186/s12974-023-03000-8. J Neuroinflammation. 2024. PMID: 38355633 Free PMC article.
References
- Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv Exp Med Biol. 2007;601:213–223. - PubMed
- Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233–4244. - PubMed
- Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–1131. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI056299/AI/NIAID NIH HHS/United States
- P20 RR021970-05/RR/NCRR NIH HHS/United States
- HL49997/HL/NHLBI NIH HHS/United States
- R01 AI034495/AI/NIAID NIH HHS/United States
- P20 GM103501/GM/NIGMS NIH HHS/United States
- R01 CA107974/CA/NCI NIH HHS/United States
- HL56067/HL/NHLBI NIH HHS/United States
- R01 HL049997/HL/NHLBI NIH HHS/United States
- P20 RR021970/RR/NCRR NIH HHS/United States
- R01 CA082689/CA/NCI NIH HHS/United States
- R01 AI34495/AI/NIAID NIH HHS/United States
- R01 CA082689-10/CA/NCI NIH HHS/United States
- R37 HL056067/HL/NHLBI NIH HHS/United States
- R01 HL056067/HL/NHLBI NIH HHS/United States
- R01 CA107974-05S1/CA/NCI NIH HHS/United States
- P01 CA142106/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous